Doxophylline Dosing and Usage in Asthma and COPD

Positioning in Treatment Algorithm

The European Respiratory Society recommends considering doxophylline as an alternative to theophylline when additional bronchodilation is needed beyond standard inhaled therapy, with a moderate strength of evidence 1, 2
The British Thoracic Society suggests that oral bronchodilators, such as doxophylline, are generally not required in mild-moderate disease but may benefit severe disease, with a low strength of evidence 3, 4

The European Respiratory Society recommends adding theophylline-class drugs, including doxophylline, after optimal inhaled bronchodilator therapy (LABA and/or LAMA), with a moderate strength of evidence 1, 2
The British Thoracic Society recommends discontinuing doxophylline if no objective improvement in spirometry or symptoms after an appropriate trial period, with a low strength of evidence 3, 4
The European Respiratory Society suggests considering inhaled corticosteroids (ICS) in appropriate phenotypes (frequent exacerbators, ACOS) before adding doxophylline, with a moderate strength of evidence 1, 2, 5

For COPD patients, consider doxophylline in moderate to severe disease (FEV1 <50-60% predicted) when patients remain symptomatic despite optimal inhaled therapy, according to the European Respiratory Society guidelines 6
Evaluate and optimize inhaled corticosteroids first in appropriate phenotypes (frequent exacerbators with ≥2 exacerbations per year, or asthma-COPD overlap syndrome) before adding doxophylline, as recommended by the European Respiratory Society guidelines 6

Conduct a formal therapeutic trial with objective spirometric assessment after 4-8 weeks of treatment, as suggested by the Thorax journal 7
Discontinue doxophylline if no objective improvement in spirometry (FEV1 increase of ≥200 mL and ≥15% from baseline) or symptoms after the trial period, according to the Thorax journal guidelines 7
Ensure proper inhaler technique is optimized before adding oral therapy, as up to 76% of COPD patients make critical errors with inhaler use, as reported in the Thorax journal 7